You blew it, Pfizer tells AstraZeneca
This article was originally published in Scrip
Executive Summary
Just ahead of the deadline of 5pm 26 May (UK time), Pfizer confirmed the news that everyone had been expecting. Following AstraZeneca's rebuttal of Pfizer's "final" acquisition proposal of 18 May, Pfizer was walking away.
You may also be interested in...
AstraZeneca 2Q: Soriot's In It For The Long Haul
AstraZeneca's CEO used the company's second-quarter earnings call to proclaim his commitment to the business just weeks after rumors spread worldwide that he might take up a vacant chief executive role at a rival firm.
Is BMS The Must Have Immuno-Oncology Accessory Of The Season?
Bristol-Myers Squibb is in the M&A hot seat, and Pfizer could be the one applying fire.
Pharma Earnings Calls Reveal US/EU Trump Divide
Less than a month after his inauguration, President Donald Trump has both unnerved and empowered industry sectors with his immediate actions or divulged potential reforms. Execs offered measured reaction and some speculation during recent earnings calls.